MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published In The Journal Of Clinical Endocrinology And Metabolism
MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published In The Journal Of Clinical Endocrinology And Metabolism
MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the publication of a peer-reviewed article highlighting results from the Phase 1 study of MBX 2109, the Company's parathyroid hormone (PTH) peptide prodrug in development for the treatment of hypoparathyroidism (HP). The publication, titled "MBX 2109, a Once-Weekly Parathyroid Hormone Replacement Therapy Prodrug: Phase 1, First-in-Human, Randomized Trial", was published in The Journal of Clinical Endocrinology and Metabolism (JCEM) and can be accessed here.
MBX生命科學公司（納斯達克股票代碼：MBX）是一家臨床階段生物製藥公司，專注於發現和開發用於治療內分泌和代謝疾病的新型精準肽治療藥物。今天宣佈，《臨床內分泌與代謝雜誌》（JCEM）發表了一篇同行評議文章，重點介紹了MBX 2109階段1研究的結果。MBX 2109是公司正在開發用於治療甲狀旁腺功能減退症（HP）的甲狀旁素（PTH）肽前藥。該文章名爲《MBX 2109，一種每週一次的甲狀旁腺激素替代治療前藥：階段1，首次進行人體隨機試驗》，可在此處閱讀。